Identification, characterization and antigenicity of the Plasmodium vivax rhoptry neck protein 1 (PvRON1)

Moreno-Perez et al.
Identification, characterization and antigenicity of the *Plasmodium vivax* rhoptry neck protein 1 (*PvRON1*)

Darwin A Moreno-Perez1,2, Marjorie Montenegro1, Manuel E Patarroyo1,3 and Manuel A Patarroyo1,2*

**Abstract**

**Background:** *Plasmodium vivax* malaria remains a major health problem in tropical and sub-tropical regions worldwide. Several rhoptry proteins which are important for interaction with and/or invasion of red blood cells, such as *PfRONs*, *Pf92*, *Pf38*, *Pf12* and *Pf34*, have been described during the last few years and are being considered as potential anti-malarial vaccine candidates. This study describes the identification and characterization of the *P. vivax* rhoptry neck protein 1 (*PvRON1*) and examine its antigenicity in natural *P. vivax* infections.

**Methods:** The *PvRON1* encoding gene, which is homologous to that encoding the *P. falciparum* apical sushi protein (ASP) according to the plasmoDB database, was selected as our study target. The *pvron1* gene transcription was evaluated by RT-PCR using RNA obtained from the *P. vivax* VCG-1 strain. Two peptides derived from the deduced *P. vivax* Sal-I *PvRON1* sequence were synthesized and inoculated in rabbits for obtaining anti-*PvRON1* antibodies which were used to confirm the protein expression in VCG-1 strain schizonts along with its association with detergent-resistant microdomains (DRMs) by Western blot, and its localization by immunofluorescence assays. The antigenicity of the *PvRON1* protein was assessed using human sera from individuals previously exposed to *P. vivax* malaria by ELISA.

**Results:** In the *P. vivax* VCG-1 strain, RON1 is a 764 amino acid-long protein. In silico analysis has revealed that *PvRON1* shares essential characteristics with different antigens involved in invasion, such as the presence of a secretory signal, a GPI-anchor sequence and a putative sushi domain. The *PvRON1* protein is expressed in parasite’s schizont stage, localized in rhoptry necks and it is associated with DRMs. Recombinant protein recognition by human sera indicates that this antigen can trigger an immune response during a natural infection with *P. vivax*.

**Conclusions:** This study shows the identification and characterization of the *P. vivax* rhoptry neck protein 1 in the VCG-1 strain. Taking into account that *PvRON1* shares several important characteristics with other *Plasmodium* antigens that play a functional role during RBC invasion and, as shown here, it is antigenic, it could be considered as a good vaccine candidate. Further studies aimed at assessing its immunogenicity and protection-inducing ability in the *Aotus* monkey model are thus recommended.

**Keywords:** Rhoptry, *Plasmodium vivax*, Antigenicity, vaccine candidate
international control strategies and policies having been implemented during the last fifty years, mortality figures are still alarming; therefore, developing an efficient vaccine to combat this imminent threat has become an urgent need.

Invasion of red blood cells (RBC) by *Plasmodium* parasites involves highly coordinated events which are directed by a set of proteins secreted from the apical organelles (rhoptries and micronemes) [4]. It has been shown that several rhoptry proteins, such as PfRON2, -4, and the PfAMA-1 antigen (secreted by micronemes), are involved in tight junction formation between the parasite and its target cell [5-7]; it has also been found that some others (such as PfRON1, Pf92, Pf38, Pf12 and Pf34) are associated with detergent-resistant membrane microdomains (DRM) through glycosylphosphatidylinositol (GPI)-anchor sequences [8], which are considered organizing centers for the assembly of molecules implicated in cell signaling [9,10]. To date, several of these DRM proteins have been shown to play an active role in host cell interaction and to trigger antibody responses in the host [11-15].

Rhoptry neck protein 1 (RON1), initially described in *Toxoplasma gondii* (TgRON1) [16], has been a particularly interesting protein. It is a highly-conserved antigen amongst *Apicomplexa* members. Different *tgon1* homologous genes have also been found in members of the *Plasmodium* genus, such as *P. falciparum* [16,17]. *PfRON1* is also known as the apical sushi protein (ASP), exhibiting a prominent transcriptional peak towards the end of the intraerythrocyte lifecycle [17]. This protein has 731 amino acids encoded by 4 exons and ~85.46 kDa molecular mass. It has been previously demonstrated that PfASP undergoes proteolytic processing, resulting in ~50 kDa and ~30 kDa polypeptides [18]. The protein also contains a signal peptide, a GPI-anchor sequence and a complement control protein (CCP) or sushi-like conserved domain [19]; this domain typically contains ~60 residues and represents a protein module involved in protein-protein interactions and/or cell adhesion, containing 4 cysteines, proline residues and highly conserved acidic amino acids (aspartic and glutamic acid). Furthermore, it has been recently found that PfRON1 has 4 high activity binding peptide sequences (HABPs) to erythrocytes (manuscript in preparation), and could thus be important for parasite entry to target cells.

In the search for an effective anti-malarial vaccine several studies have been focused on identifying antigens expressed during the parasite’s asexual stage due to the fact that some of these antigens are mainly responsible for invasion of RBC [20,21]. Several proteins included in developing a promising vaccine against *P. falciparum* have been functionally characterized to date [21]. However, studies carried out with *P. vivax* have been limited due to the difficulty in maintaining an *in vitro* continuous parasite culture. Taking this into account and considering the degree of conservation observed between the genetic content of different *Plasmodium* species [23,24], some bioinformatics tools have been used for homology searches of the complete *P. vivax* genome for antigens already described in *P. falciparum*. To date, a considerable number of surface [25-28] and rhoptry proteins [22,29-35] have been experimentally identified and characterized in *P. vivax* using both its genome [21] and intraerythrocyte lifecycle transcriptome [36] as well as an *Aotus*-adapted strain [37]. These proteins belong to a list of antigens, which are being tested as vaccine candidates in the *Aotus* monkey model.

This study shows the identification and characterization of the *PrRON1* protein which is homologous to *PfASP*. Different aspects such as *PrRON1* transcription and expression at the end of the intraerythrocyte life cycle, the subcellular localization pattern and the ability to trigger an immune response in patients who have presented active episodes of *P. vivax* malarial infection have been determined by molecular biology and immunochemistry techniques.

**Methods**

**Bioinformatics analysis**

The *P. vivax ron1* gene sequence (which is homologous to the *PfASP* encoding gene) was obtained from the plasmoDB database [38]; likewise, *pfasp* orthologous genes in other malarial species were searched. Identity and similarity values between *P. falciparum - P. vivax* and *P. vivax - P. knowlesi* hypothetical protein products were determined using ClustalW software [39]. The presence of a signal peptide, repeat sequences and a GPI-anchor sequence was determined by SignalP 3.0 [40], XSTREAM repeat [41] and GPI-anchor [42] bioinformatics tools, respectively. Putative domains were assessed using the Interpro database [43]. Antheprot software [44] was used for determining two peptides throughout the *PvRON1* hypothetical sequence (PlasmoDB accession number: PVX_000945) that could be good B-cell epitopes, taking the highest average hydrophilicity (>4.9), solvent accessibility (>162) and Parker’s antigenicity (>37.8) values into account (calculated in a 20 residue sliding window), according to previously established parameters [45-47].

**Animal handling**

The experimental handling of animals used here was carried out in accordance with Colombian Law 84/1989 and resolution 504/1996. *Aotus* monkeys kept at FIDIC’s primate station (Leticia, Amazon) and New Zealand rabbits provided by the Instituto Nacional de Salud
(Bogotá, Colombia) were handled following the guidelines for the care and use of laboratory animals (National Institute of Health, USA) under the constant supervision of a veterinarian. Immunization and bleeding procedures for Aotus monkeys had been previously approved by our institute's ethics committee, and were carried out in agreement with the conditions stipulated by Corpoamazonia (resolution 00066, September 13th, 2006). A monkey from the Aotus genus was experimentally infected with the VCG-1 strain (Vivax Colombia Guaviare 1) and subjected to daily monitoring to assess the progress of infection throughout the whole study (up to day 18) using acridine orange staining. The monkey was treated with pediatric doses of chloroquine (10 mg/kg on the first day and 7.5 mg/kg/day until the fifth day) and primaquine (0.25 mg/kg/day from the third to the fifth day) at the end of the study to guarantee total blood parasite clearance. Once experiments were over, Corpoamazonia officers supervised the primate's return to its natural habitat in excellent health conditions.

**Isolating the P. vivax parasite**

The VCG-1 strain was obtained according to a previously described methodology [37]. Mature forms of the parasite, mainly schizonts, were purified from a blood sample (3 mL) infected with P. vivax using a Percoll discontinuous gradient (GE Healthcare, Uppsala, Sweden), according to a previously established protocol [48]. This schizont-enriched sample was then used for performing all of the following procedures: RNA, genomic DNA or parasite total protein extraction, as well as indirect immunofluorescence assays.

**RNA extraction and cDNA synthesis**

Total RNA from the schizont-enriched sample was extracted using the Trizol method and treated with RNase-free RQ1 DNase (Promega, Wisconsin, USA), according to the manufacturer’s instructions. 5 μL RNA were used to synthesize cDNA by RT-PCR, using the SuperScript III enzyme (Invitrogen, California, USA). Complementary DNA synthesis was carried out in the following conditions: 65°C for 5 mins, 50°C for 1 hour and 70°C for 15 mins. After a 15-min incubation period with RNase (Promega, USA) at 37°C, the product was stored at -20°C until its use.

**Cloning and sequencing**

Three specific primer sets were designed to cover the whole gene sequence and produce two smaller-sized recombinant fragments (Forward 5’-ACAGAAGAGAGAGAGACAGAGACAGA-3’, Reverse 5’-GGTTCACACATCCGGGT-CAC-3’; Forward 5’-ATGGGAGAAGCGCCCAAGTG-3’, Reverse 5’-ATCCCTAGCAATGCTTCG-3’; Forward 5’-ATGCGCTAGTGCCACCGC-3’, Reverse 5’-CTGAAACACATCGAAATCG-3’). After PCR amplification using the Platinum Pfx DNA polymerase enzyme (Invitrogen, California, USA), each product was purified by Wizard PCR preps kit (Promega), ligated to the pEX5 CT/TOPO vector (Invitrogen) and cloned in Escherichia coli TOP10 bacteria (Invitrogen), following the manufacturer's instructions. Recombinant DNA was purified using an UltraClean mini plasmid prep purification kit (MO BIO laboratories, California, USA) and each sequence's integrity was confirmed by sequencing two clones obtained from independent PCRs, using the automated genetic analyzer ABI PRISM 310 (PE Applied Biosystems, California, USA).

**Peptide synthesis and polyclonal antibody production**

Two 20-amino-acid-long peptides designed on the PvRON1 deduced sequence (Sal-1 strain) (CG-KHKEGGAAKRHKKPEHEQRG-GC and CG-EDAS-VADKDQQPGERQDGQ-GC) were synthesized according to a previously established methodology [49], polymerized, lyophilized and characterized by RP-HPLC and MALDI-TOF MS. Afterwards, a 150 μg dose of a mixture from both synthetic peptides, emulsified in Freund’s complete adjuvant (FCA) (Sigma, Missouri, USA), was inoculated into New Zealand rabbits on day 0, while the same mixture emulsified in Freund’s incomplete adjuvant (FIA) was inoculated on days 21 and 42. Sera were collected before the first immunization (pre-immune sera) and 20 days after the last booster dose (post III sera). Rabbit sera were absorbed with E. coli proteins coupled to a Sepharose column and then stored at -20°C until use, according to the manufacturer’s instructions (Amersham Biosciences, Buckinghamshire, UK).

**Parasite protein extraction**

A parasite pellet was treated with 0.2% saponin, then washed six times with PBS and homogenized in lysis buffer (5% SDS, 10 mM PMSF, 10 mM iodoacetamide, 1 mM EDTA). The total lysate was quantified by using a micro BCA protein assay kit (Thermo scientific) and resolved in SDS-PAGE in reducing and non-reducing conditions. Immunoblot detection was carried out using sera from rabbits previously immunized with synthetic peptides.

**Isolating detergent-resistant microdomains (DRMs)**

Parasite mature forms extracted by the Percoll method were treated with 0.2% saponin in PBS for 5 minutes. After six washes in PBS, the pellet was suspended in a 200 μL TNET solution (1% Triton X-100, 25 mM Tris-HCl, 150 mM NaCl and 1 mM EDTA) which contained protease inhibitors (1 mM PMSF, 1 mM iodoacetamide,
The sample was poured into two aliquots which were then treated in the following conditions: a 100 μL aliquot was incubated at 4°C for 30 minutes and subsequently centrifuged at 7,550 rpm for 10 minutes; the remaining sample was kept at 37°C for 30 minutes and then centrifuged in the same conditions described above. The supernatant was recovered in a new Eppendorf tube and the remaining pellet from each assay was suspended in lysis buffer (5% SDS, 10 mM PMSF, 10 mM iodoacetamide, 1 mM EDTA). Each fraction was quantified by Micro BCA protein assay kit (Thermo scientific) and resolved in 12% SDS-PAGE.

Expression and purification of recombinant protein fragments

Once the sequence from cloned inserts had been confirmed, these were transformed in the E. coli BL21-AI strain (Invitrogen), according to the manufacturer’s recommendations. In brief, cells were grown overnight at 37°C and then inoculated in Terrific broth medium supplemented with 0.1 mg/mL ampicillin and 0.1% (w/v) D-glucose. Once the cells had reached their stationary phase (0.6 OD600), 0.2% L-arabinose (w/v) was added as inductor and these were incubated again in the same conditions described above for 4 hours. The culture was centrifuged at 13,000 rpm for 30 minutes and the pellet was suspended in extraction buffer (6 M Urea, 12 mM imidazol, 10 mM Tris-Cl, 100 mM NaH₂PO₄ and 10 mg/mL lysozyme) supplemented with protease inhibitors (1 mM PMSF, 1 mM iodoacetamide, 1 mM EDTA and 1 mg/mL leupeptin) and lysed by sonication. rPvRON1-a and rPvRON1-c recombinant fragment expression was assessed on 12% SDS-PAGE. pEXP5 CT/TOPO vector was used to facilitate purification and recognition by monoclonal anti-histidine antibodies. This vector adds a six-histidine tag towards the C-terminus of each fragment, which is used for purifying the recombinant protein by affinity chromatography using a Ni⁺²-NTA resin (Qiagen, California, USA). Briefly, the extraction buffer described above was used to elute the recombinant proteins and then the same buffer plus 500 mM imidazole was used to elute the recombinant protein. All individually collected fractions were analyzed by SDS-PAGE and Western blot. Pure fractions were dialyzed in PBS pH 7.0. The protein was ultrafiltered and concentrated using an Amicon filtration system (LabX scientific marketplace, Midland Canada) and quantified with a micro BCA protein assay kit (Thermo Fisher scientific, Pittsburgh, PA, USA).

SDS-PAGE and Western blot

5 μg of each recombinant and 50 μg of both parasite total lysate and the fractions obtained in DRMs were separated on SDS-PAGE gels and transferred to nitrocellulose membranes. These membranes were blocked with 5% skimmed milk in 0.05% PBS-Tween for one hour. After three washes with 0.05% PBS-Tween, each membrane was cut into strips which were individually analyzed as follows: strips with recombinant protein were incubated for 1 hour at room temperature in 5% skimmed milk in 0.05% PBS-Tween, including a 1:100 dilution of rabbit (pre-immune and post-III) or human sera. Strips with parasite total lysate and those containing DRM fractions were incubated for 1 hour at room temperature in 5% skimmed milk in 0.05% PBS-Tween, including a 1:100 dilution of anti-PvRON1 antibodies. After 3 washes, strips were incubated for 1 hour with goat anti-rabbit IgG coupled to phosphatase as secondary antibody in a 1:4,500 dilution at room temperature, or goat anti-human IgG in a 1:5,000 dilution. Western blot for recombinant proteins was carried out as follows: a nitrocellulose strip was used as positive control; this strip was incubated with a peroxidase-coupled monoclonal anti-histidine antibody diluted 1:4,500 in skimmed milk plus 0.05% PBS-Tween. Blots were revealed with a substrate peroxidase VIP kit (Vector Laboratories, Burlington, Canada) or BCIP/NBT color development substrate kits (Promega), according to the manufacturer’s instructions.

Indirect immunofluorescence assay (IFA)

Blood smears from the Aotus monkey infected with P. vivax were fixed with 4% (v/v) formaldehyde. Slides were washed thrice with PBS and blocked at 37°C for 45 minutes using a 1% (v/v) bovine serum albumin (BSA) solution in PBS. After 3 washes, slides were incubated at 37°C for 1 hour with a mixture of anti-PvRON1 rabbit sera in 1:30 dilution and anti-PvRhopH3 mice sera (previously obtained in our institute [30]) in 1:40 dilution, suspended in PBS -1% BSA - 0.1% Triton X-100 solution. After three washes, plates were incubated with FITC-conjugated anti-rabbit IgG antibody (Sigma) and Red-conjugated anti-mouse IgG antibody (Millipore) in 1:30 dilution and 50 μg/mL of both parasite total lysate and the fractions obtained in DRMs were separated on SDS-PAGE gels and transferred to nitrocellulose membranes. These membranes were blocked with 5% skimmed milk in 0.05% PBS-Tween for one hour. After three washes with 0.05% PBS-Tween, each membrane was cut into strips which were individually analyzed as follows: strips with recombinant protein were incubated for 1 hour at room temperature in 5% skimmed milk in 0.05% PBS-Tween, including a 1:100 dilution of rabbit (pre-immune and post-III) or human sera. Strips with parasite total lysate and those containing DRM fractions were incubated for 1 hour at room temperature in 5% skimmed milk in 0.05% PBS-Tween, including a 1:100 dilution of anti-PvRON1 antibodies. After 3 washes, strips were incubated for 1 hour with goat anti-rabbit IgG coupled to phosphatase as secondary antibody in a 1:4,500 dilution at room temperature, or goat anti-human IgG in a 1:5,000 dilution. Western blot for recombinant proteins was carried out as follows: a nitrocellulose strip was used as positive control; this strip was incubated with a peroxidase-coupled monoclonal anti-histidine antibody diluted 1:4,500 in skimmed milk plus 0.05% PBS-Tween. Blots were revealed with a substrate peroxidase VIP kit (Vector Laboratories, Burlington, Canada) or BCIP/NBT color development substrate kits (Promega), according to the manufacturer’s instructions.

Accession number: the nucleotide and amino acid sequences used here have been reported in the GenBank database, under accession number JN188400.

Results and Discussion

Pvron1 gene identification and localization in a syntenic chromosome region

The initial P. vivax ron1 gene sequence selected for this study was found in the plasmoDB database (Accession number PVX_000945). According to the information
found there, the ron1 gene seemed to be ubiquitous within the *Plasmodium* genus, since orthologous genes were found in the *Plasmodium falciparum*, *Plasmodium knowlesi* and *Plasmodium berghei* genomes. Additionally, the database showed that open reading frame (ORF) orientation and exon-intron structure were highly conserved among the genes encoding the hypothetical protein products in these parasite species. Such genome organization was consistent with the identity (Id) and similarity (S) values obtained when *P. falciparum* - *P. vivax* and *P. vivax* - *P. knowlesi* contigs were analyzed (Figure 1). It is worth noting that the high degree of S observed between *P. vivax* - *P. knowlesi* was in agreement with the evolutionary proximity found in a previous phylogenetic analysis of conserved regions from the circumsporozoite protein (CSP) encoding gene [50] and in a comparative genomics study of *P. vivax* [23] which showed that these organisms share similar chromosomal regions. Interestingly, the Id value found between the alignment of ORFs encoded by *pfasp* (PFD0295c) and *pvron1* (PVX_000945) genes was similar to the Id values found in antigens considered good candidates for designing an effective vaccine against *P. vivax* malaria [22,28,29], suggesting that *PrRON1* should be an interesting candidate for immunological trials.

**PvRON1 characterization in silico**

The *pvron1* gene from SAL-1 strain has 2,801 bp; it encodes to a 772 amino acid-long protein (~84.5 kDa estimated molecular weight). This protein is 41 residues longer compared to *PfASP* (731 aa) [18]. *PvRON1* presents two hydrophobic regions in the N and C-terminus matching a secretory signal sequence composed by the first 21 amino acids and another located between amino acids 743 to 764 (Figure 2A). This latter feature plus the result of the GPI-anchor predictor, point out to the C-terminal anchoring of this protein by GPI. In addition, a sushi-like domain (also known as complement control protein (CCP) module) was predicted; this domain consists of 56 amino acids, four corresponding to cysteines (Cys) which intervene in the domain’s structural conformation to mediate protein-protein binding and/or cell adhesion [19].

XSTREAM analysis revealed a tandem repeat (TR) between amino acids 148 to 171 (Figure 2A). According to the alignment performed with other homologous proteins in *Plasmodium* species (*P. falciparum*, *P. knowlesi* and *P. chabaudi*) this region has been shown to be exclusive for *P. vivax* (Figure 2B). The TR consists of four blocks of eight amino acids having the EKLPIGGG consensus sequence. Antheprot software prediction has shown that this could be a good B-cell lineal epitope. Another two blocks having a similar sequence to that of the TR were found between amino acids 133 to 147; these sequences showed substitutions or deletions of some residues, suggesting that this region might be under selective pressure. It has been previously described that the polymorphic repeat sequences found in some *P. falciparum* malarial antigens, such as the circumsporozoite protein (CSP), the ring-infected erythrocyte surface antigen (RESA) and the S-antigen, can affect antibody affinity maturation and mask critical epitopes involved in invasion from being recognized [51-54]; the present analysis has thus led us to suggesting that the TR regions found in *PrRON1* could be part of a mechanism used by the parasite to evade the host’s humoral immune response. However, further experimental evidence is needed to confirm this hypothesis.

**The pvron1 gene is transcribed during the blood stage**

The presence of *ron1* gene transcripts in the *P. vivax* VCG-1 strain was assessed by PCR, using cDNA as template. Figure 2C shows the amplification products obtained from RT-PCR and genomic DNA, indicating that the *pvron1* gene is transcribed in schizont-enriched samples. These results agreed with previously reported

---

**Figure 1** Schematic scale organization showing the localization of *pfasp* (PFD0295c), *pvron1* (PVX_000945) and *pkron1* (PCH_030870) genes within *P. falciparum*, *P. vivax* and *P. knowlesi* chromosome fragments. Exon-intron organization, ORF orientation and gene IDs are shown in accordance with the plasmoDB database. Identity (Id) and similarity (S) values between each hypothetical protein product contained in *P. falciparum* - *P. vivax* and *P. vivax* - *P. knowlesi* upstream and downstream contigs are shown.
studies showing a peak transcription from 35 to 40 hours of the *P. vivax* Sal-1 strain intraerythrocyte cycle [36] and between 35 and 48 hours in the *P. falciparum* 3D7 strain [17]. Once genomic and complementary DNA sequences were aligned, it was found that the *pvron1* gene was encoded by four exons, similar to the homologous *pfasp* gene [18], the fourth of them containing a sushi domain. Two nucleotide substitutions and a thirty-two base pair deletion corresponding to a repeat block (EKLPIGGG) were observed when the *pvron1* gene sequences from Sal-1 reference strain and VCG-1 *Aotus*-adapted strain were compared. These mutations were non-synonymous and produced changes in the following amino acids: glutamic acid for glycine in position 148 and isoleucine for threonine in position 740. Furthermore, 17 Cys residues were shown to be conserved between these two strains. When comparing these residues from the *PvRON1* sequence with its *P. falciparum* homologue (*PfASP*), these presented an identical localization, suggesting that there was probably a degree of conservation in the 3D structure of such molecules.

**PvRON1 expression and association with DRMs**

Two peptides derived from the deduced *P. vivax* Sal-1 *PvRON1* sequence were synthesized and inoculated in rabbits for obtaining anti-*PvRON1* antibodies that could recognize the protein in parasite lysate. The antibodies’ ability to recognize *PvRON1* was assessed by Western blot, using purified r*PvRON1*-a and r*PvRON1*-c fragments expressed as recombinants. (B) Alignment of a *RON1* protein-fragment from *P. falciparum*, *P. vivax*, *P. chabaudi* and *P. knowlesi* species. This figure shows the region consisting of amino acids 120 to 210, which includes a repeat sequence which is exclusive for *P. vivax* species. Asterisks indicate identical amino acids. A dot refers to weakly similar amino acids and two dots indicate strongly similar amino acids. (C) *pvron1* gene amplification by PCR. Line 1 shows the molecular weight marker. Lines 2 and 3 correspond to amplification of genomic and complementary DNA.

**Figure 2** In silico characterization, alignment of a *RON1* protein-fragment in different malarial species and *pvron1* gene transcription

(A) *pvron1* gene scheme, showing the signal peptide, GPI-anchor sequence, TR and sushi domain localizations. Cysteine residues are represented by lines. Peptides used for rabbit immunization are shown, as well as r*PvRON1*-a and r*PvRON1*-c fragments expressed as recombinants. (B) Alignment of a *RON1* protein-fragment from *P. falciparum*, *P. vivax*, *P. chabaudi* and *P. knowlesi* species. This figure shows the region consisting of amino acids 120 to 210, which includes a repeat sequence which is exclusive for *P. vivax* species. Asterisks indicate identical amino acids. A dot refers to weakly similar amino acids and two dots indicate strongly similar amino acids. (C) *pvron1* gene amplification by PCR. Line 1 shows the molecular weight marker. Lines 2 and 3 correspond to amplification of genomic and complementary DNA.
(Figure 3B; Line 2), polyclonal antibodies detected bands at ~100 kDa, ~57 kDa and ~42 kDa in the pellet soluble fraction at 4°C, and in the treatment soluble fraction at 37°C (Figure 3B; lines 8 and 10); these bands disappeared when the pellet was treated with the non-ionic detergent at 37°C (Figure 3B; line 12). Interestingly, sera revealed bands in the soluble fraction at 4°C (Figure 3B; line 6), which can be attributed to the high protein expression levels during schizont stage. Together, these results led to confirming that PvRON1 antigen was associated with DRMs, differing from what has been reported in the DRM proteome study [15].

**Localization in rhoptries**

An immunofluorescence assay was carried out on a blood smear of *P. vivax*-infected RBCs for assessing the protein’s subcellular localization in the parasite. Figure 4A shows *PvRON1* distribution in mature schizonts as a punctuated fluorescence pattern, which is characteristic of apical organelle proteins (rhoptries and micronemes). Alternatively, double labeling was carried out using anti-*PvRhopH3* mouse antibodies (rhoptry bulb marker) and anti-*PvRON1* rabbit antibodies (Figure 4B). Overlapping images showed partial localization of both proteins, supporting the fact that *PvRON1* antigen could be forming part of the rhoptry neck, as occurs with *P. falciparum* ASP protein [56].

**PvRON1 antigenicity**

Two fragments located towards the N- and C-termini of the *pvron1* gene were cloned, transformed and
expressed as recombinants proteins. Each purified protein’s antigenicity was evaluated by Western blot using sera from 20 patients living in *P. vivax* malarial endemic regions in Colombia and who had had active episodes of the disease. Sera from four individuals who had never suffered from malaria were used as negative controls. All individuals signed an informed consent after receiving detailed information regarding the study goals. Most sera, except for that from controls, presented reactivity towards *rPvRON1-a* and *rPvRON1-c* (Figure 5A and 5B) fragments, suggesting that *PvRON1* is expressed during natural malarial infection and that it can also trigger antibody responses in the host. It has been demonstrated that antibodies directed against antigenic proteins can inhibit parasite-host interaction [21] and, therefore, these have been considered as potential candidates in designing a vaccine against malaria. All the above supports the notion that *PvRON1* may be a promising candidate for further trials aimed at assessing its immunogenicity and protection-inducing ability in the *Aotus* monkey model.

**Conclusions**

This study has described the identification and characterization of a DRM-associated rhoptry protein. Taking into account the multiple particularities of *PvRON1* identified here (i.e. the gene’s transcription, the protein’s expression towards the end of the intraerythrocyte lifecycle and its localization and the broad recognition presented by sera from individuals infected with *P. vivax*), it can be suggested that this protein is a good vaccine candidate. The presence of secretory and GPI-anchor signals and a domain probably involved in invasion also suggested that the *PvRON1* antigen could play a functional role during RBC invasion; further immunogenicity and protection-inducing ability studies are thus needed in the *Aotus* experimental model to confirm the value of this protein or its products, as components of a multi-epitope, subunit-based vaccine against *P. vivax* malaria.

**Acknowledgements**

We would like to thank Rafael Areiza and Nohora Guayacan for their technical support and Jason Garry for translating and reviewing this manuscript.

**Author details**

1. Fundación Instituto de Inmunología de Colombia (FIDIC), Carrera 50 No. 26-20, Bogotá, Colombia. 2. Universidad del Rosario, Calle 63D No. 24-31, Bogotá, Colombia. 3. Universidad Nacional de Colombia, Carrera 45 No. 26-85, Bogotá, Colombia.

**Authors’ contributions**

DAMP designed experiments, analyzed data and wrote the initial manuscript. MM carried out molecular biology and immunochemical assays. MEP and MAP evaluated and coordinated the assays, and corrected the final manuscript. All authors read and approved the final manuscript.

---

**Figure 5 Western blot analysis showing the recognition of *PvRON1* recombinant fragments by human sera.** (A-B) *rPvRON1-a* and *rPvRON1-c* detection. Lines 1-21, detection with sera from *P. vivax*-infected patients; Lines 22-25, recognition by control patients’ sera; Line 26, detection of the protein using anti-polyhistidine monoclonal antibody.
Competing interests
The authors declare that they have no competing interests.

Received: 14 July 2011 Accepted: 24 October 2011

References
1. WHO: World malaria report 2010. The WHO global malaria programme. Geneva, 2010.
2. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005, 434:214-217.
3. Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 2001, 64:97-106.
4. Coxman AF, Crabb BS. Invasion of red blood cells by malaria parasites. Cell 2006, 124:755-766.
5. Alexander DL, Mital J, Ward GE, Bradley P, Boothroyd JC. Invasion of red blood cells by malaria parasites. Parasitol Int 2009, 58:29-35.
6. Alexander DL, Arastu-Kapur S, Dubremetz JF, Boothroyd JC. Plasmodium falciparum AMA1 binds a rhoptry neck protein homologous to TgRlON1, a component of the moving junction in Toxoplasma gondii. Eukaryotic cell 2006, 5:1169-1173.
7. Gilson PR, Nebl T, Vukcevic D, Moritz RL, Sargeant T, Speed TP, Schofield L. Identification and biochemistry of glycosylphosphatidylinositol-anchored membrane proteins of the human malaria parasite Plasmodium falciparum. Mol Cell Proteomics 2006, 5:1286-1299.
8. Allen JA, Halverston-Tamboli RA, Rasenick MM. Lipid raft microdomains and neurotransmitter signalling. Nat Rev Neurosci 2007, 8:128-140.
9. Murphy SC, Hiller NL, Harrison T, Lomasney JW, Mohandas N, Haldar K. Lipid rafts and malaria parasite infection of erythrocytes. Mol Pathol 2006, 3:81-88.
10. Schofield L, Vivas L, Hackett F, Gerold P, Schwartz RT, Tachado S. Neutralizing monoclonal antibodies to glycosylphosphatidylinositol, the dominant TNF-alpha-inducing toxin of Plasmodium falciparum: prospects for the immunotherapy of severe malaria. Ann Trop Med Parasitol 1993, 87:617-626.
11. Garcia J, Curtidor H, Pinzon CG, Vanegas M, Moreno A, Patarroyo ME. Identification of conserved erythrocyte binding regions in members of the Plasmodium falciparum Cys5 lipid raft-associated protein family. Vaccine 2009, 27:3953-3962.
12. Obando-Martinez AZ, Curtidor H, Arevalo-Pinzon G, Vanegas M, Vizcaino C, Patarroyo MA, Patarroyo ME. Conservation high activity binding peptides are involved in adhesion of two detergent-resistant membrane-associated merozoite proteins to red blood cells during invasion. J Med Chem 2010, 53:3907-3918.
13. Arevalo-Pinzon G, Curtidor H, Vanegas M, Vizcaino C, Patarroyo MA, Patarroyo ME. Conservation high activity binding peptides from the Plasmodium falciparum Pf34 rhoptry protein inhibit merozoites in vitro invasion of red blood cells. Peptides 2010, 31:1987-1994.
14. Sanders PR, Gilson PR, Cantis GT, Greenbaum DC, Nebl T, Carucci DJ, McConville MJ, Schofield L, Hodder AN, Yates JR, Crabb BS. Distinct protein classes including novel merozoite surface antigens in Raft-like membranes of Plasmodium falciparum. J Biol Chem 2005, 280:6049-6056.
15. Bradley PJ, Ward WC, Cheng SJ, Alexander DL, Collar S, Coombs GH, Dunn JD, Ferguson DJ, Sanderson SJ, Wathling JM, Boothroyd JC. Proteomic analysis of rhoptry organelles reveals many novel constituents for host-parasite interactions in Toxoplasma gondii. J Biol Chem 2005, 280:34245-34258.
16. Bozdech Z, Llinas M, Pulliam BL, Wong ED, Zhu J, DeRisi JL. The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum. PLoS Biol 2003, 1:15.
17. O’Sheaife AH, Green L, Grainger M, Holder AA. A novel Sushi domain-containing protein of Plasmodium falciparum. Mol Biochem Parasitol 2005, 140:61-68.
18. O’Leary JM, Bromek K, Black GM, Uhinova S, Schmitz C, Wang X, Kych M, Atkinson JP, Uhrin D, Barlow PN. Backbone dynamics of complement control protein (CCP) modules reveals mobility in binding surfaces. Protein Science 2004, 13:1238-1250.
19. Patarroyo ME, Patarroyo MA. Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines. Accorts Chem Res 2008, 41:377-386.
20. Rodríguez LE, Curtidor H, Urquiza M, Cifuentes G, Reyes C, Patarroyo ME. Intimate molecular interactions of P. falciparum merozoite proteins involved in invasion of red blood cells and their implications for vaccine design. Chem Rev 2008, 108:3666-3703.
21. Moreno-Perez DA, Mongui A, Sober LN, Sanchez-Ladino M, Patarroyo MA. Identifying and characterizing a member of the RhoH1/Claig family in Plasmodium vivax. Gene 2011, 481(1):17-23.
22. Carlton JM, Adams JH, Silva JC, Bidwell SL, Lorenzi H, Caler E, Crabtree J, Anguïou SV, Menino EF, Amedeo P, Cheng Q, Coulson RM, Crabb BS, Del Portillo HA, Essien K, Feldblyum TV, Fernandez-Becker C, Gilson PR, Guaye AH, Guo X, Kang K, Kooi J, Korinscky M, Meyer EV, Nene V, Paulsen I, White O, Raphael SA, Ren Q, Sargeant TJ, Sabbleg SA, Stoedект C, Sullivan SA, Yamamoto MM, Hoffman SL, Wortman JR, Gardner MJ, Galinski MR, Barnwell JW, Fraser-Liggott CM. Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature 2008, 455:757-763.
23. Carlton J, Silva J, Hall N. The genome of model malaria parasites, and comparative genomics. Current issues in molecular biology 2005, 7:23-37.
24. Mongui A, Angel DI, Moreno-Perez DA, Villarreal-Gonzalez S, Almonacid H, Vanegas M, Patarroyo MA. Identification and characterization of the Plasmodium vivax thrombospondin-related apical merozoite protein. Malar J 2010, 9:283.
25. Mongui A, Perez-Leal Q, Soto SC, Cortes J. Patarroyo MA. Cloning, expression, and characterization of a Plasmodium vivax MSP7 family merozoite surface protein. Biochem Biophys Res Commun 2006, 351:639-644.
26. Perez-Leal O, Sierra AY, Barrero CA, Moncada C, Martinez P, Cortes J, Lopez Y, Salazar LM, Hoebeke J, Patarroyo MA. Identifying and characterising the Plasmodium falciparum merozoite surface protein 10 Plasmodium vivax homologue. Biochem Biophys Res Commun 2005, 331:1178-1184.
27. Perez-Leal O, Sierra AY, Barrera CA, Moncada C, Martinez P, Cortes J, Lopez Y, Torres E, Salazar LM, Patarroyo MA. Plasmodium vivax merozoite surface protein 8 cloning, expression, and characterization. Biochem Biophys Res Commun 2004, 324:1393-1399.
28. Mongui A, Angel DI, Gallego G, Reyes C, Martinez P, Guhl F, Patarroyo MA. Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34kDa rhoptry antigen (Pv34), Vaccine 2009, 28:415-421.
29. Arevalo-Pinzon G, Curtidor H, Fatino LC, Patarroyo MA. PvRON2, a new Plasmodium vivax rhoptry neck antigen. Malar J 2011, 10:60.
30. Mongui A, Angel DI, Guzman C, Vanegas M, Patarroyo MA. Characterization of the Plasmodium vivax Pv38 antigen. Biochem Biophys Res Commun 2008, 376:326-330.
31. Mongui A, Perez-Leal O, Rojas-Caraballo J, Angel DI, Cortes J, Patarroyo MA. Identifying and characterizing the Plasmodium falciparum RhoH3 Plasmodium vivax homologue. Biochem Biophys Res Commun 2007, 358:861-866.
32. Mongui A, Perez-Leal O, Arilda J, Vanegas M, Patarroyo MA. The Plasmodium vivax Pv41 surface protein: identification and characterization. Biochem Biophys Res Commun 2008, 377:1113-1117.
33. Patarroyo MA, Perez-Leal O, Lopez Y, Cortes J, Rojas-Caraballo J, Gomez A, Moncada C, Rivas J, Patarroyo ME. Identification and characterisation of the Plasmodium vivax rhoptry-associated protein 2. Biochem Biophys Res Commun 2005, 337:853-859.
34. Perez-Leal O, Mongui A, Cortes J, Yepes G, Leiton J, Patarroyo MA. The Plasmodium vivax rhoptry-associated protein 1. Biochem Biophys Res Commun 2008, 341:1053-1058.
35. Bozdech Z, Mok S, Hu G, Inwong M, Jaidne A, Russell B, Ginsburg H, Noden F, Day NP, White NJ, Carlton JM, Peiser PR. The transcriptome of Plasmodium vivax reveals divergence and diversity of transcriptional regulation in malaria parasites. Proc Natl Acad Sci USA 2008, 105:16290-16295.
36. Pico de Coina Y, Rodriguez J, Guerrero E, Barrero C, Rodriguez R, Mendoza M, Patarroyo MA. A highly infective Plasmodium vivax strain.
adapted to Aotus monkeys: quantitative haematological and molecular determinations useful for *P. vivax* malaria vaccine development. *Vaccine* 2003, 21:3930-3937.

38. PlasmoDB: *Plasmodium* genomics resource. [http://www.plasmodb.org](http://www.plasmodb.org).

39. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res* 1994, 22:4673-4680.

40. Bendtsen JD, Nielsen H, von Heijne G, Brunak S. Improved prediction of signal peptides: SignalP 3.0. *J Mol Biol* 2004, 340:783-795.

41. Newman AM, Cooper JB. XSTREAM: a practical algorithm for identification and architecture modeling of tandem repeats in protein sequences. *BMC bioinformatics* 2007, 8:382.

42. Poisson G, Chauve C, Chen X, Bergeron A. FragAnchor: a large-scale predictor of glycosylphosphatidylinositol anchors in eukaryote protein sequences by qualitative scoring. *Genomics, proteomics & bioinformatics/Beijing Genomics Institute* 2007, 5:121-130.

43. Hunter S, Apweiler R, Attwood TK, Barroso J, Binns D, Bork P, Brain SN, Chandonia JM, Ferro S, Gough J, Haft D, Hulo N, Huynen MA, et al. The InterPro database. *Nucleic Acids Res* 2009, 37:D225-D230.

44. Deleage G, Combet C, Blanchet C, Geourjon C. ANTHEPROM: an integrated protein sequence analysis software with client/server capabilities. *Computers in Biology and Medicine* 2001, 31:259-267.

45. Jain J, Wodak S. Conformation of amino acid side-chains in proteins. *J Mol Biol* 1978, 125:357-386.

46. Hopp TP, Woods KR. Prediction of protein antigenic determinants from amino acid sequences. *Proc Natl Acad Sci USA* 1981, 78:3824-3828.

47. Welling GW, Weijer WJ, van der Zee R, Welling-Wester S. Prediction of sequence antigenic regions in proteins. *FEBS Lett* 1985, 188:215-218.

48. Andrysiak PM, Collins WE, Campbell GH. Concentration of *Plasmodium* ovale and *Plasmodium vivax*-infected erythrocytes from nonhuman primate blood using Percoll gradients. *Am J Trop Med Hyg* 1986, 35:251-254.

49. Houghten RA. General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. *Proc Natl Acad Sci USA* 1985, 82:13213-13217.

50. Escalette AA, Barrio E, Ayala FJ. Evolutionary origin of human and primate malarial: evidence from the circumsporozoite protein gene. *Molecular biology and evolution* 1995, 12:616-626.

51. Chitnis CE. Localization of apical sushi protein in *Plasmodium falciparum* merozoites. *Mol Biochem Parasitol* 2010, 174:66-69.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Cite this article as: Moreno-Perez et al. Identification, characterization and antigenicity of the *Plasmodium vivax* rhoptry neck protein 1 (PRON1), *Malaria Journal* 2011 10:314.

doi:10.1186/1475-2875-10-314